Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Dasatinib in Adult Ph-like Acute Lymphoblastic Leukemia
NCT03564470Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2016
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of tucidinostat and dasatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Event-Free Survival at 3 years. Status: unknown.
02
Drugs
tucidinostatdasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03564470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564470.